aTyr Pharma, Inc.
NASDAQ:ATYRBiotechnology
+$0.07 today
- Market cap
- $52.13M
- Beta
- 0.54
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$0.71
Volume 1.02M
Average 2.29M
ATYR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
aTyr Pharma, Inc.NASDAQ: ATYR
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$10.4M, compared with -$14.5M a year earlier. Trailing-twelve-month EBITDA was -$68.69M.
Context
- EBITDA amounted to 38192.1% of revenue in FY2025, up 11604.0 pp from a year earlier.
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -$39.42M (+45.7%) for the fiscal year ending Dec 2026, a step up from the -16.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$10.4M+23.4% QoQ
- Last fiscal yearDec 2025
- -$72.57M-16.1% YoY
- LTMMar 2026
- -$68.69M-10.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +28.3% | — | — |
| 1 year | -16.1% | +45.7% | +61.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (72.57M) USD
- Year-over-year change
- -16.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (72.57M) | -16.1% |
| FY2024 | 2024-12-31 | (62.48M) | -31.1% |
| FY2023 | 2023-12-31 | (47.66M) | -9.2% |
| FY2022 | 2022-12-31 | (43.65M) | -34.4% |
| FY2021 | 2021-12-31 | (32.47M) | — |
EBITDA vs competitors
How ATYR compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -10.6% is the 5th highest of 8, against a peer median of -1.2%.
- EBITDA amounts to 36154.2% of revenue for ATYR, versus a peer median of 89.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | -CA$10.88M CAD | +76.6% | — | 59.3% |
| LTM Mar 2026 | -$39.25M USD | -164.0% | — | — | |
| LTM Mar 2026 | -$40.42M USD | -143.9% | — | 89.7% | |
| LTM Mar 2026 | -$52.24M USD | -1.2% | — | 1327.8% | |
| LTM Mar 2026 | -$58.88M USD | -297.6% | — | — | |
| LTM Mar 2026 | -$68.69M USD | -10.6% | — | 36154.2% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$82.08M USD | +0.7% | — | — |
| LTM Mar 2026 | -$86.7M USD | +32.0% | — | — | |
| Peer median (excluding ATYR) | — | -1.2% | — | 89.7% | |
Competitors are the stored peer set for ATYR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 10.39M | 353K | 235K | 190K |
| Cost of Revenue | 1.3M | 1.7M | 0 | 0 | 1.55M |
| Gross Profit | (1.3M) | 8.69M | 353K | 235K | (1.36M) |
| Gross Margin | — | 83.7% | 100.0% | 100.0% | -717.4% |
| Research & Development | 23.26M | 42.81M | 42.29M | 54.37M | 60.22M |
| Selling, General & Admin | 10.75M | 12.29M | 12.98M | 13.78M | 17.6M |
| Operating Expenses | 32.71M | 55.1M | 55.27M | 68.15M | 76.26M |
| Depreciation & Amortization | 1.3M | 1.7M | 2.74M | 1.54M | 1.55M |
| EBITDA | (32.47M) | (43.65M) | (47.66M) | (62.48M) | (72.57M) |
| EBITDA Margin | — | -420.3% | -13500.3% | -26588.1% | -38192.1% |
| Operating Income | (34.02M) | (46.4M) | (54.92M) | (67.91M) | (77.63M) |
| Operating Margin | — | -446.8% | -15557.8% | -28899.6% | -40856.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 238K | 1.06M | 4.52M | 3.89M | 3.51M |
| Income Before Tax | (33.78M) | (45.34M) | (50.4M) | (64.02M) | (74.12M) |
| Pre-Tax Margin | — | -436.6% | -14276.8% | -27243.4% | -39009.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (33.77M) | (45.34M) | (50.39M) | (64.02M) | (74.12M) |
| Net Margin | — | -436.5% | -14274.5% | -27243.8% | -39009.5% |
| EPS (Basic) | (1.77) | (1.60) | (0.94) | (0.86) | (0.80) |
| EPS (Diluted) | (1.77) | (1.60) | (0.94) | (0.86) | (0.80) |
| Weighted Avg Shares | 19.08M | 28.42M | 53.61M | 74.26M | 92.99M |
| Weighted Avg Shares (Diluted) | 19.08M | 28.42M | 53.61M | 74.26M | 92.99M |
aTyr Pharma, Inc.
NASDAQ:ATYR
Intrinsic Alpha fair value
Locked
Current Price
$0.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.